trending Market Intelligence /marketintelligence/en/news-insights/trending/e_vFLipKeKvNK8gPisJj9Q2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

Biogen to buy back $5B of common stock

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Biogen to buy back $5B of common stock

Biogen Inc.'s board authorized to repurchase up to $5 billion of the company's common stock.

The 2019 share repurchase program has no expiration date, the Cambridge, Mass.-based biotechnology company said.

Biogen, which focuses on neurodegenerative diseases, said the new repurchase program is in addition to the about $1.7 billion remaining under a $3.5 billion buyback program launched in August 2018.

Biogen stocks dropped more than 29% after news that the company and Japan's Eisai Co. Ltd. will be discontinuing two late-stage clinical trials of their Alzheimer's drug aducanumab. Biogen shares fell to $226.88 as of the close of U.S. trading March 21, down 29.23%.